MX2022010437A - Tratamiento mejorado de la dermatitis atopica con tradipitant. - Google Patents

Tratamiento mejorado de la dermatitis atopica con tradipitant.

Info

Publication number
MX2022010437A
MX2022010437A MX2022010437A MX2022010437A MX2022010437A MX 2022010437 A MX2022010437 A MX 2022010437A MX 2022010437 A MX2022010437 A MX 2022010437A MX 2022010437 A MX2022010437 A MX 2022010437A MX 2022010437 A MX2022010437 A MX 2022010437A
Authority
MX
Mexico
Prior art keywords
tradipitant
atopic dermatitis
patient
improved treatment
treatment
Prior art date
Application number
MX2022010437A
Other languages
English (en)
Inventor
Mihael H Polymeropoulos
Gunther Birznieks
Christos Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2022010437A publication Critical patent/MX2022010437A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La descripción se refiere generalmente a mejoras en el tratamiento del prurito, la dermatitis atópica (DA) y sus síntomas asociados, con tradipitant. Más particularmente, se refiere a un método para aumentar la probabilidad de lograr una respuesta terapéutica óptima en el tratamiento de un paciente con DA, donde el paciente con DA es uno para el que una terapia potencial de elección puede incluir la administración de una cantidad de un antagonista de NK-1, por ejemplo, tradipitant, eficaz para tratar la DA del paciente.
MX2022010437A 2020-02-25 2021-02-24 Tratamiento mejorado de la dermatitis atopica con tradipitant. MX2022010437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062981481P 2020-02-25 2020-02-25
PCT/US2021/019376 WO2021173641A1 (en) 2020-02-25 2021-02-24 Improved treatment of atopic dermatitis with tradipitant

Publications (1)

Publication Number Publication Date
MX2022010437A true MX2022010437A (es) 2022-09-07

Family

ID=74875372

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010437A MX2022010437A (es) 2020-02-25 2021-02-24 Tratamiento mejorado de la dermatitis atopica con tradipitant.

Country Status (10)

Country Link
US (1) US20230226046A1 (es)
EP (1) EP4110335A1 (es)
JP (1) JP2023515167A (es)
KR (1) KR20220145844A (es)
CN (1) CN115052599A (es)
AU (1) AU2021227900A1 (es)
CA (1) CA3169449A1 (es)
IL (1) IL295327A (es)
MX (1) MX2022010437A (es)
WO (1) WO2021173641A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2298513T3 (es) 2002-04-26 2008-05-16 Eli Lilly And Company Derivados de tiazol como antagonistas del receptor de taquicinina.
CA2542140C (en) 2003-10-24 2012-05-29 Eli Lilly And Company Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
JP7347743B2 (ja) * 2017-09-13 2023-09-20 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2020023898A1 (en) * 2018-07-27 2020-01-30 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat chronic pruritus
WO2020023879A1 (en) * 2018-07-27 2020-01-30 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat pruritus associated with atopic dermatitis

Also Published As

Publication number Publication date
KR20220145844A (ko) 2022-10-31
EP4110335A1 (en) 2023-01-04
US20230226046A1 (en) 2023-07-20
JP2023515167A (ja) 2023-04-12
WO2021173641A1 (en) 2021-09-02
AU2021227900A1 (en) 2022-09-15
IL295327A (en) 2022-10-01
CN115052599A (zh) 2022-09-13
CA3169449A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
Soin et al. High-frequency electrical nerve block for postamputation pain: a pilot study
MX2009011540A (es) Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo.
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
Nakamura et al. Effects of galvanic vestibular stimulation combined with physical therapy on pusher behavior in stroke patients: a case series
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
MX2023003993A (es) Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
MX2022016243A (es) Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca.
GB0308323D0 (en) Electromagnetic stimulation in patients with osteoporosis
MX2022010437A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
WO2019139956A3 (en) Prevention and treatment of organ fibrosis
MX2021007490A (es) Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides.
Yaghobi et al. Comparison of tap water and normal saline iontophoresis in idiopathic hyperhidrosis: a case report
MX2021001549A (es) Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
RU2199303C1 (ru) Способ вибротерапии нейровегетативной формы вазомоторного ринита
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
GB0405381D0 (en) A method and means for treating heart failure
Amiri et al. Effect of Repetitive Transcranial Magnetic Stimulation on Reducing Spasticity in Patients Suffering From HTLV-1–Associated Myelopathy
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
Odell Jr et al. New technique combines electrical currents and local anesthetic for pain management
US20180028297A1 (en) Unbalanced tongue-pressing occluder
Zhang et al. Induction of hyperalgesia in pigs through blocking low hydraulic resistance channels and reduction of the resistance through acupuncture: A mechanism of action of acupuncture
WO2017123667A3 (en) Non-ischemic heart failure treatment by cell therapy
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
Fursule et al. Effect of cervical mobilization, transcutaneous electrical stimulation and suboccipital release in cervicogenic headache: A case report